Mucopolysaccharidosis IIIB is a paediatric lysosomal storage disease caused by deficiency of the enzyme a-N-acetylglucosaminidase (NAGLU), involved in the degradation of the glycosaminoglycan heparan sulphate. Absence of NAGLU leads to accumulation of partially degraded heparan sulphate within lysosomes and the extracellular matrix, giving rise to severe CNS degeneration with progressive cognitive impairment and behavioural problems. There are no therapies. Haematopoietic stem cell transplant shows great efficacy in the related disease mucopolysaccharidosis I, where donor-derived monocytes can transmigrate into the brain following bone marrow engraftment, secrete the missing enzyme and cross-correct neighbouring cells. However, little neurological correction is achieved in patients with mucopolysaccharidosis IIIB. We have therefore developed an ex vivo haematopoietic stem cell gene therapy approach in a mouse model of mucopolysaccharidosis IIIB, using a high-titre lentiviral vector and the myeloidspecific CD11b promoter, driving the expression of NAGLU (LV.NAGLU). To understand the mechanism of correction we also compared this with a poorly secreted version of NAGLU containing a C-terminal fusion to IGFII (LV.NAGLU-IGFII). Mucopolysaccharidosis IIIB haematopoietic stem cells were transduced with vector, transplanted into myeloablated mucopolysaccharidosis IIIB mice and compared at 8 months of age with mice receiving a wild-type transplant. As the disease is characterized by increased inflammation, we also tested the anti-inflammatory steroidal agent prednisolone alone, or in combination with LV.NAGLU, to understand the importance of inflammation on behaviour. NAGLU enzyme was substantially increased in the brain of LV.NAGLU and LV.NAGLU-IGFII-treated mice, with little expression in wild-type bone marrow transplanted mice. LV.NAGLU treatment led to behavioural correction, normalization of heparan sulphate and sulphation patterning, reduced inflammatory cytokine expression and correction of astrocytosis, microgliosis and lysosomal compartment size throughout the brain. The addition of prednisolone improved inflammatory aspects further. Substantial correction of lysosomal storage in neurons and astrocytes was also achieved in LV.NAGLU-IGFII-treated mice, despite limited enzyme secretion from engrafted macrophages in the brain. Interestingly both wild-type bone marrow transplant and prednisolone treatment alone corrected behaviour, despite having little effect on brain neuropathology. This was attributed to a decrease in peripheral inflammatory cytokines. Here we show significant neurological disease correction is achieved using haematopoietic stem cell gene therapy, suggesting this therapy alone or in combination with anti-inflammatories may improve neurological function in patients. Keywords: lysosomal storage disease; microglia; mucopolysaccharidosis; neurodegeneration; stem cells Abbreviations: AAV = adeno-associated virus; CS = chondroitin sulphate; DS = dermatan sulphate; HSCGT = haematopoietic stem cell gene therapy; HSCT = haematopoietic stem cell transplant; IB4 = isolectin B4; IGFII = insulin-like growth factor 2; LV = lentiviral vector; MPSIIIB = mucopolysaccharidosis IIIB; UA = uronic acid
Introduction
Mucopolysaccharidosis IIIB (MPSIIIB or Sanfilippo B syndrome) is a neurodegenerative lysosomal storage disease caused by a deficiency in the glycosaminoglycan degrading enzyme, a-N-acetylglucosaminidase (NAGLU). NAGLU deficiency results in the global accumulation of partially degraded heparan sulphate in cells, leading to cellular dysfunction, which is particularly apparent in the brain. Symptom onset begins within the first 2 to 4 years of life, characterized by a plateau in development, speech delay, and worsening behavioural problems, together with minor somatic indicators such as organomegaly and facial dysmorphia. Progressive motor impairment follows leading to greatly shortened life expectancy. There are currently no effective treatments.
Enzyme replacement therapy has successfully treated somatic disease in other mucopolysaccharidosis disorders. Crosscorrection occurs via mannose-6-phosphate mediated enzyme uptake by deficient cells. However, the inability of delivered enzyme to cross the blood-brain barrier limits its worth in MPSIIIB, where the main pathology is neurological. Approaches to deliver enzyme via an intracerebroventricular route are in progress, but these methods are invasive. A C-terminal fusion of NAGLU to insulin-like growth factor 2 (rhNAGLU-IGFII), which also binds the mannose-6-phosphate receptor leads to more efficient uptake, lysosomal targeting and activity following intracerebroventricular injection in MPSIIIB mice (Kan et al., 2014a, b) .
Another option for patients with MPSIIIB is delivery of adeno-associated virus (AAV)-based gene therapy vectors via a variety of routes to treat the brain (Fu et al., 2002 (Fu et al., , 2007 (Fu et al., , 2010 Cressant et al., 2004) . One hurdle in developing these therapies is achieving effective vector distribution from the sites of injection, something that can be effectively achieved in rodents but not in patients to date (Tardieu et al., 2014 (Tardieu et al., , 2017 .
Haematopoietic stem cell transplant (HSCT), enables donor haematopoietic stem cells to repopulate bone marrow of myeloablated recipients, with donor-engrafted leucocytes secreting enzyme to cross-correct somatic cells. Bone marrow-derived monocytes are also able to cross the blood-brain barrier and engraft within the brain, enabling cross-correction within the CNS. Although effective in patients with mucopolysaccharidosis I, several studies have shown poor neurological outcomes following HSCT in patients with MPSIIIB (Vellodi et al., 1992; Shapiro et al., 1995) , despite successful clearance of heparan sulphate in somatic organs. This failure is thought to be due to poor endogenous secretion of NAGLU from engrafted donor macrophages in the brain. Cord blood transplantation has had greater success in MPSIIIB patients (Prasad et al., 2008) , but behaviour is not corrected, despite improved survival. A retroviral-mediated haematopoietic stem cell gene therapy (HSCGT) approach in MPSIIIB mice, designed to overcome this failing, was found to have disappointing efficacy and the effect reduced with time (Zheng et al., 2004) .
We have previously demonstrated in the clinically similar disease MPSIIIA that ex vivo gene delivery of N-sulphoglucosamine sulphohydrolase (SGSH) to haematopoietic stem cells using a clinically approved lentiviral vector (LV), driven by the myeloid-specific CD11b promoter, led to restoration of 11% wild-type activity of SGSH in the brains of MPSIIIA mice, normalized heparan sulphate storage and CNS pathology and corrected behaviour , whereas wild-type transplantation was unsuccessful . CD11b is highly expressed by monocyte/macrophage/microglial cells, leading to enhanced transgene expression in the brain compared to the ubiquitous phosphoglycerate kinase promoter. This approach is now under development for clinical trial (Bigger and Wynn, 2014) .
We applied this HSCGT methodology in the MPSIIIB mouse model, comparing MPSIIIB mice receiving wildtype haematopoietic stem cells versus MPSIIIB haematopoietic stem cells transduced with a vector expressing either NAGLU (LV.NAGLU) or a poorly secreted version of NAGLU fused to IGFII (LV. NAGLU-IGFII) (Kan et al., 2014b) . This allowed us to study the role of NAGLU expressing donor macrophages in the brain, including the inflammatory cytokine/chemokine effects that they mediate, in the context of limited NAGLU secretion.
There are several anti-inflammatories now used clinically to manage abnormal behaviour (Reale et al., 2012; Felger and Lotrich, 2013) . Given that peripheral cytokines impact directly on brain pathology, prednisolone, a corticosteroid that has limited ability to cross the blood-brain barrier, was used to treat MPSIIIB mice to test the effect of somatic correction of inflammation on brain disease. Notably, however, prednisolone is not recommended in patients due to significant side effects not seen in rodents. A combined prednisolone and LV.NAGLU HSCGT group was also included. We demonstrate significantly increased brain NAGLU activity, normalized heparan sulphate brain storage, reduced neuroinflammation and secondary storage and behavioural correction with LV-mediated HSCGT using both vectors, highlighting the effectiveness of our LV.NAGLU vector approach for correction of brain disease in MPSIIIB. No brain correction was seen following wild-type HSCT. Prednisolone treatment additionally reduced somatic tissue inflammation, providing enhanced benefit when used in combination with LV.NAGLU HSCGT, but all treatments improved hyperactive behaviour.
Materials and methods
Generation and in vitro testing of LV.NAGLU and LV.NAGLU-IGFII Codon optimized human NAGLU (GenBank Õ accession number NM_000263.3) flanked with attB1 and attB2 sites (manufactured by GeneArt) was cloned using the gateway system (Life Technologies) into the pCCL lentiviral vector backbone downstream of the CD11b promoter , to generate pCCLsin.cPPT.hCD11b.NAGLU.WPRE (LV.NAGLU). NAGLU-IGFII fusion plasmid comprising full-length NAGLU, a short unstructured linker, the c-Myc epitope EQKLISEED and amino acids 32-91 of IGFII (GenBank Õ accession number NM_001007139.4) was kindly donated by Patricia Dickson (Kan et al., 2014b) . PCR, using extended primers designed to incorporate attB1 and attB2 sites either side of NAGLU-IGFII, was used to amplify the NAGLU-IGFII segment, which was then agarose gel purified and cloned using the gateway system into the lentiviral vector genome plasmid described above to generate pCCLsin.cPPT.hCD11b.NAGLU-IGFII.WPRE (LV.NAGLU-IGFII). A GFP lentiviral vector in the same vector backbone (pCCLsin.cPPT.hCD11b.eGFP) was used as a control (LangfordSmith et al., 2012) . Lentiviral vector was produced and titred as described previously Sergijenko et al., 2013) . CHME3 cells were transduced at a multiplicity of infection of 10, collecting media and cells after 48 h.
Mice, haematopoietic stem cell isolation, transduction and transplantation All in vivo procedures were ethically approved in accordance with Home Office regulations. Mice were housed in a 12/12-h light/dark cycle with food and water provided ad libitum. MPSIIIB (B6.129S6-Naglu tm1Efn /J, strain 003827, Jackson Laboratory) mice were backcrossed with C57BL/6J mice (CD45.2) or B6.SJL-Ptprc a Pepc b /BoyJ (strain 002014, Jackson Laboratory, CD45.1) mice to distinguish between donor and recipient haematopoietic cells. Bone marrow was isolated from donor CD45.1-MPSIIIB mice, lineage depleted and haematopoietic stem cells transduced with a multiplicity of infection of 60 as described previously . Recipient mice at 2 months of age were treated with intraperitoneal 125 mg/kg busulfan (Busilvex; Pierre Fabre) over 5 days prior to tail vein injection of 3 Â 10 5 LV-transduced haematopoietic stem cells. Whole bone marrow from CD45.1-WT mice (10 7 ) was injected into busulfan-conditioned MPSIIIB mice for wildtype HSCT treated mice. Prednisolone was added at 6 mg/l ($1 mg/kg/day) in drinking water from 6 weeks in control mice or 14 weeks following LV-mediated HSCGT. The survival curve was limited by Home Office licence regulations, meaning that mice had to be culled when they showed significant signs of disease; typically urine retention and loss of body condition. A cohort of untreated wild-type littermates suffered from alopecia (without other signs of distress) from 13 months, requiring sacrifice.
Donor chimerism
Haematopoietic stem cell engraftment was assessed in peripheral blood following staining with anti-mouse CD45.1-PE (donor) and CD45.2-FITC (recipient) (both BD Pharmingen) antibodies and analysed on a BD FACS Canto II flow cytometer. Animals where chimerism was 560% were excluded.
Tissue harvesting
At 8 months of age, mice were anaesthetized, the right atrium cut to allow blood collection into citrate buffer for plasma and white blood cells and transcardially perfused with warmed phosphate-buffered saline (PBS) to remove blood, as described previously . One brain hemisphere and liver pieces were fixed in 4% paraformaldehyde for 24 h, before washing with PBS. Brain hemispheres were placed into 30% sucrose 2 mM MgCl 2 for 24 h before freezing at À80 C for 30 mm coronal microtomy. Liver was transferred into 70% ethanol for paraffin mounting and slicing. The second brain hemisphere and remaining organs were frozen at À80 C. Bone marrow was isolated from the hind legs of mice and set up in MethoCult TM culture (Stem Cell Technologies) as previously described to assess colony forming unit (CFU) lineage development.
Vector copy number determination
Vector copy number was determined from harvested tissue using quantitative PCR as described .
Enzyme assays
Tissue was homogenized in 0.5 M NaCl/0.02 M Tris, 0.1% v/v Triton TM X-100, pH 7-7.5, then centrifuged at 2200g, storing the supernatant. Protein concentration was determined using Pierce BCA assay kit (Fisher Scientific). For NAGLU enzymatic assay, 10-60 mg of total protein was incubated with NAGLU substrate (4-methylumbelliferyl-N-acetyl-a-D-glucosaminide, Sigma) for 4 h at 37 C, resulting in release of fluorescent 4-methylumbelliferone. Stop buffer (0.2 M carbonate buffer, pH 9.5) was then added and the fluorescence measured immediately at excitation 360 nm and emission 460 nm using a Synergy HT Microplate reader (BioTec) against known 4-methylumbelliferone standards. For assessment of b-N-acetyl hexosaminidase (b-Hex) activity, 1-2 mg total protein was incubated with 4-methylumbelliferyl-N-acetyl-b-D-glucosaminide for 40 min at 37 C. Stop buffer was then added and the fluorescence measured.
Glycosaminoglycan analysis
Brain and liver samples were homogenized in PBS/1% Triton TM X-100 and a small sample taken for protein quantification. Tissues were digested with pronase (Roche) and glycosaminoglycans purified as described previously (Holley et al., 2011) . Glycosaminoglycan samples were then divided into two; one aliquot was digested with heparinase I/II/III and labelled with 2-aminoacridone as described previously (Holley et al., 2011) , the second was digested with 2 mIU chondroitinase ABC (Sigma) and 2-aminoacridone labelled. Both heparan sulphate and chondroitin sulphate/dermatan sulphate (CS/DS) disaccharides were subject to reverse phase-HPLC using a Zorbax Eclipse XBD-C18 column (Agilent) equilibrated in 95% 0.1 M ammonium acetate/5% acetonitrile, running on an Agilent 1200 Series HPLC system. Disaccharides were eluted over a 5-20% gradient of acetonitrile at 0.2 ml/min, detecting in-line fluorescence at excitation 425 nm and emission 520 nm. 2-Aminoacridone-labelled CS/DS or heparan sulphate disaccharide standards (Iduron) were used for peak identification. For calculation of micrograms of heparan sulphate or CS/DS, total fluorescence was compared with the fluorescence from known quantities of heparan sulphate or dermatan sulphate. Correction factors were calculated (Supplementary Table 1) as described (Deakin and Lyon, 2008) .
Measurement of cytokine/chemokine level
MIP-1a (CCL3), IL-1a, MCP-1 (CCL2), KC (CXCL1) and RANTES (CCL5) were measured in brain, liver and plasma using Cytomeric Bead Array flex sets (BD Biosciences) according to manufacturer's instructions.
Open field behaviour
Open field behaviour was performed as previously described (Langford-Smith et al., 2011a, b) . The data were analysed using Ethovision XT11.5 software (Noldus).
Immunohistochemistry
Free-floating immunohistochemistry was performed on seven coronal brain sections (30 mm) from matched areas of Bregma (0.98, 0.14, À0.46, À1.06, À1.70, À2.40 and À3.28 mm) as described previously (Malinowska et al., 2010; Sergijenko et al., 2013) . Paraffin-embedded liver sections (5 mM) were dewaxed and rehydrated prior to staining, processing as above. Primary antibodies included rat anti-LAMP2 (Abcam), rabbit anti-NeuN (Abcam), peroxidase-conjugated BSI-B4 (Sigma), rabbit anti-GFAP (DakoCytomation), and mouse anti-GM2 (a gift from Dr Konstantin Dobrenis); secondary antibodies included goat anti-rabbit Alexa Fluor Õ 594, goat anti-rat Alexa Fluor Õ 488 (Life Technologies) and Biotinylated-goat anti-mouse IgM (Vector laboratories). DAPI was used to highlight nuclei. Isolectin B4 (IB4) stained slides were counterstained with Mayer's haemotoxylin. Images were acquired on a 3D-Histech Pannoramic-250 microscope slide-scanner using a 20Â/0.30 Plan Achromat objective (Zeiss) and the DAPI, FITC and TRITC filter sets and processed using Case Viewer software (3D-Histech).
Experimental design
Four experimental groups were compared against wild-type or MPSIIIB control mice. Mice were analysed for behaviour (n = 14-22) and for biochemistry and histology (n = 6-10). N numbers were based on previous power calculations as seen in the MPSIIIA mouse model and behavioural changes in the MPSIIIB mouse model (Langford-Smith et al., 2011b) . It was impossible to blind in vivo treatment groups, due to the nature of the mouse model, treatments given and experiment size, with transplants staggered over several months, yet treatment groups were filled equally to avoid bias. Analyses were carried out in a blinded fashion.
Statistical analysis
GraphPad Prism was used for one-way or two-way ANOVA and Tukey post hoc test for analysis. Significance was P 5 0.05%.
Results

Efficient expression of NAGLU from lentiviral vectors
We constructed a lentiviral vector expressing either human NAGLU or human NAGLU fused to amino acids 32-91 of IGFII (Kan et al., 2014b) , both under the control of the myeloid-specific CD11b promoter (Fig. 1A) . Over-expression of active NAGLU enzyme was confirmed in the human microglial cell line CHME3, using LV.eGFP as a control. Significant increases of 5.5-fold and 6.2-fold in intracellular NAGLU activity was seen with LV.NAGLU and LV.NAGLU-IGFII, respectively (Fig. 1B) , without noticeable toxicity. Secreted activity was increased 9.9-fold with LV.NAGLU but minimal secretion was observed with LV.NAGLU-IGFII (Fig. 1C ), providing us with a tool to study the effect of restricting NAGLU expression to engrafted cells, with little cross-correction of neighbouring cells.
To determine whether ex vivo transduction of MPSIIIB haematopoietic stem cells can effectively treat the mouse model of MPSIIIB following transplant, we set-up seven treatment groups in vivo ( for daily injections, and its previous efficacy in MPSIIIB animals (DiRosario et al., 2009) . Average vector copy number measured in HSC-enriched bone marrow at transplant was similar at 7.4-0.8 vector copy numbers per cell (Fig. 1E) . Consequently, NAGLU activity in HSC-enriched bone marrow was substantially increased above wild-type levels in all LV-mediated HSCGT groups (8.4-fold over wild-type in LV.NAGLU, 8.9-fold in LV.NAGLU-IGFII, and 7.6-fold in PRED + LV.NAGLU) with no significant differences between groups (Fig. 1F) . Equally there were no significant differences in the total number of CFUs or the proportion of each colony type obtained from wild-type, MPSIIIB or MPSIIIB haematopoietic stem cells transduced with either lentiviral vector ( Fig. 1G and H) , suggesting no NAGLU or lentiviral vector toxicity in haematopoietic stem cells. Over 82% donor peripheral blood chimerism was achieved in all transplant groups at 6 months of age, with no significant difference between groups (Fig. 1I) .
A proportion of mice in each group were culled at 8 months of age to assess efficiency of therapy. Remaining mice were kept for long-term analysis, sacrificing at their humane endpoint. Mean survival was 9.4 months in untreated MPSIIIB mice and prednisolone treated mice ( Fig. 1J and K) , typically due to urine retention as seen previously (Gografe et al., 2009) . Survival was significantly increased in wild-type HSCT and LV-mediated HSCGT groups, with reduced incidence of urine retention.
Lentiviral-mediated HSCGT results in significantly increased NAGLU activity compared to wild-type HSCT Mice sacrificed at 8 months of age were used for biochemical and immunohistological analysis. There was no significant difference in the total number of bone marrow-derived CFUs ( Supplementary Fig. 1A ) or in the percentage of CFUs of different lineage types ( Supplementary Fig. 1B ) suggesting no toxicity of transgene or vector.
Vector copy number and NAGLU activity were measured in white blood cells, plasma, bone marrow, brain, spleen and liver (Fig. 2) . No significant differences in vector copy number were seen between LV-mediated HSCGT treatment groups in white blood cells, bone marrow, brain or liver; however, in all organs tested there was a trend towards higher vector copy numbers in the LV.NAGLU group versus prednisolone + LV.NAGLU ( Fig. 2 and Supplementary Fig.  2 ). A significant difference between groups was seen in spleen, with 10 vector copy numbers in the LV.NAGLU group compared to 4.3 in PRED + LV.NAGLU. This is likely due to the reduced vector copy number in transplanted haematopoietic stem cells between these groups (Fig. 1E) .
No detectable NAGLU enzyme activity was found in MPSIIIB tissues. All treatments except prednisolone increased NAGLU activity compared to untreated MPSIIIB. NAGLU activity was increased in white blood cells to 221% of wild-type in wild-type HSCT animals, compared to 3741%, 1853% and 1905% in LV.NAGLU, LV.NAGLU-IGFII and PRED + LV.NAGLU groups, respectively (Fig. 2B ). Plasma NAGLU levels were 287% of wild-type with LV.NAGLU, but only 14% of wild-type was seen in LV.NAGLU-IGFII animals, suggesting little secretion of NAGLU-IGFII occurs in vivo (Fig. 2D) , mirroring results in vitro (Fig. 1C) . Little plasma NAGLU was apparent in wild-type HSCT animals, suggesting that native NAGLU secretion is low from haematopoietic cells. Bone marrow NAGLU activity was increased to 89% of wildtype with wild-type HSCT and 175% of wild-type in LV.NAGLU-IGFII (Fig. 2G) . Substantially increased bone marrow NAGLU levels were seen in LV.NAGLU and PRED + LV.NAGLU groups (1240% and 780%, respectively). Positive correlations were seen between vector copy number and enzyme overexpression ( Supplementary Fig. 2 ).
Brain NAGLU activity was only increased significantly compared to MPSIIIB in LV-mediated HSCGT groups (Fig. 2J) . Wild-type NAGLU levels of 1.3% were seen with wild-type HSCT, compared to 13% with LV.NAGLU and 8.6% with LV.NAGLU-IGFII. Six per cent enzyme activity was achieved in PRED + LV.NAGLU Figure 1 Continued 48 h after transduction at an multiplicity of infection of 10. (D) Groups used for in vivo study. Groups 1 (wild-type, WT) and 2 (MPSIIIB) are untreated control animals. In Group 3 myeloablated 2-month-old MPSIIIB mice received wild-type HSCT using whole bone marrow. In Group 4, 2-month-old myeloablated MPSIIIB mice were transplanted with HSC-enriched MPSIIIB bone marrow transduced with LV.NAGLU. In Group 5 myeloablated MPSIIIB mice received HSC-enriched MPSIIIB bone marrow that had been transduced with LV.NAGLU-IGFII. Group 6 mice received prednisolone delivered in drinking water from 2 months of age. A combined therapy was delivery to Group 7 whereby myeloablated MPSIIIB mice received HSC-enriched bone marrow transduced with LV.NAGLU at 2 months of age, followed by prednisolone delivered in drinking water (PRED + LV.NAGLU). Thus Groups 4, 5 and 7 (LV.NAGLU, LV.NAGLU-IGFII and PRED + LV.NAGLU) all received LV-mediated HSCGT treatments. White blood cell analysis and behaviour was performed on all mice at 6 months of age. Six to 10 mice were harvested at 8 months (6 months post-transplant) for biochemical and histological analysis. A cohort (n = 10-18) was kept for survival and sacrificed at their humane endpoint. (E and F) Vector copy number (E) and NAGLU enzyme activity (F) of HSC-enriched MPSIIIB bone marrow used for transplants. (G and H) LV-transduced HSC-enriched MPSIIIB bone marrow cells at transplant were cultured for 12 days in methylcellulose culture, counting the resulting colony types (G). Total colony numbers per 2500 cells plated is shown in H. (I) Donor chimerism in white blood cells was determined using flow cytometry at 6 months post-transplant. (J) Kaplan-Meier survival curve. A cohort of 10-18 mice per group were kept for long term analysis and sacrificed at their humane endpoint. In untreated MPSIIIB and prednisolone-treated mice this was typically due to urine retention. (K) Mean survival in months for each group. Significance is indicated by lines with *P 5 0.05, **P 5 0.01, ***P 5 0.001 and ****P 5 0.0001. Error bars represent standard error of the mean (SEM). Significant differences were calculated using a one-way ANOVA, *P 5 0.05, **P 5 0.01, ***P 5 0.001 and ****P 5 0.0001. Significance to wild-type is shown above bars, all other comparisons are shown using a line. VCN = vector copy number.
groups, probably reflecting the respective vector copy number in transplanted haematopoietic stem cells (Figs 1E and 2I) . In spleen and liver, all treatments increased NAGLU enzyme levels, with the greatest correction achieved with HSCGT ( Fig. 2M and P) .
Lysosomal function is important to maintain cellular homeostasis, with increased lysosomal size often leading to dysregulated expression of other lysosomal enzymes (Sardiello et al., 2009) . MPSIIIB mice exhibited increased b-Hex activity over wild-type in all tissues examined (Fig. 2C, E, H, K, N and Q) . Wild-type HSCT and LVmediated HSCGT transplant groups exhibited a reduction in b-Hex in somatic tissues. However, significant reductions in b-Hex in the brain were only seen in LV-mediated HSCGT groups (Fig. 2K) , paralleling the upregulation of NAGLU seen in the brain of these animals.
Normalization of glycosaminoglycan storage in the brains of lentiviralmediated HSCGT-treated mice Loss of NAGLU results in the accumulation of partially degraded heparan sulphate, therefore primary heparan sulphate storage was measured in the liver and brain of control and treated mice to determine the effectiveness of therapy ( Fig. 3 and Supplementary Fig. 3 ). In the liver, a 21-fold increase in heparan sulphate was seen in MPSIIIB mice, which was normalized to near wild-type levels in both wildtype HSCT and all HSCGT treatment groups (Fig. 3A) . However, in the brain, only LV-mediated HSCGT groups showed normalized heparan sulphate storage, with only a marginal non-significant decrease in wild-type HSCT mice (Fig. 3C) . A slight decrease in accumulated heparan sulphate in liver and brain was also seen with prednisolone treatment, but this was non-significant (Fig. 3A) .
Analysis of the heparan sulphate disaccharide composition revealed abnormalities in several sulphated disaccharide units in MPSIIIB mice in both liver (Fig 3B) and brain (Fig  3D) . In the brain 76% of all disaccharides were N-sulphated ( Supplementary Fig. 3B ), coupled with 2.7-fold and 2.0-fold increases in 2-O-sulphation and 6-O-sulphation, respectively. Consistent with reductions in heparan sulphate levels, brain heparan sulphate patterning was only corrected with LV-mediated HSCGT, whereas liver heparan sulphate patterning and sulphation was normalized in all HSCGT and wild-type HSCT groups ( Fig. 3 and Supplementary  Fig. 3 ). These dramatic increases in total heparan sulphate and in heparan sulphate sulphation in MPSIIIB are likely to present both a physical and functional barrier to normal cellular function. Thus normalization of brain heparan sulphate storage and patterning following HSCGT should restore heparan sulphate-protein binding homeostasis.
NAGLU enzyme is not directly involved in CS/DS degradation, however secondary storage of other lysosomal substrates might be expected, therefore we measured CS/DS in the liver and brain of control and treated animals. The main disaccharide CS/DS units found in the liver were uronic acid-N-acetyl-galactosamine 4S,6S [ÁUA-GalNAc(4S,6S)] and uronic acid-N-acetyl-galactosamine 4S [ÁUA-GalNAc(4S)], with few 2-O-sulphate-containing residues ( Fig. 3 and Supplementary Fig. 3 ). 6-O-sulphation was significantly increased in MPSIIIB animals together with a 4.1-fold increase over wild-type in total CS/DS. Total CS/DS was significantly decreased in the liver of both wild-type HSCT and all HSCGT groups and interestingly, also those treated with prednisolone alone (Fig. 3E) . Normalization of 6-O-sulphation levels was also apparent in all transplant groups; however, CS/DS patterning was not corrected in prednisolone mice (Fig. 3F) , despite the decrease in CS/DS burden.
In the brain, the major CS/DS component is ÁUA-GalNAc(4S) with no detectable 2-O-sulphation and few 6-O-sulphate containing disaccharides. No secondary storage of CS/DS or alterations in CS/DS sulphation were apparent between wild-type and MPSIIIB animals ( Fig. 3H and Supplementary Fig. 3D ).
Inflammatory cytokines are only reduced in the brain of lentiviralmediated HSCGT-treated mice
Lysosomal accumulation of heparan sulphate and secondary storage products lead to inflammation, with many chemokines/cytokines binding directly to heparan sulphate, leading to their capture at the cell surface. Significant upregulation of MIP-1a, IL-1a, MCP-1 and KC protein was noted in the brain of MPSIIIB mice at 8 months of age ( Fig. 4A-D) . Wild-type HSCT resulted in little or no effect on these levels. Prednisolone treatment alone had no effect on these cytokines in the brain. LV-mediated NAGLU overexpression using either LV-vector in all HSCGT groups resulted in complete normalization of MIP-1a, IL-1a and MCP-1 in the brain (Fig. 4A-C) , with expression reduced to wild-type levels.
A reduction in inflammatory chemokines was also seen in the periphery; liver MIP-1a, IL-1a, MCP-1, KC and RANTES and circulating plasma IL-1a, MCP-1 and KC were reduced in all LV-mediated HSCGT groups, as well as in wild-type HSCT mice, probably due to the normalization of heparan sulphate levels in the periphery. Mice that received the anti-inflammatory prednisolone also exhibited significantly suppressed levels of these inflammatory cytokines in the liver and plasma, indeed dropping below wild-type. Additional reductions in cytokine levels were seen with PRED + LV.NAGLU in the periphery, suggesting synergistic effects of combined treatments. This highlights that although prednisolone does not appear to directly affect brain inflammation, it acts to significantly reduce inflammation in the periphery. Error bars represent SEM. Significant differences were calculated using a two-way ANOVA using Tukey post hoc test, *P 5 0.05, **P 5 0.01, ***P 5 0.001 and ****P 5 0.0001. Significance to wild-type is shown above bars, all other comparisons are illustrated using a line. (M-P) Open field behaviour was performed for 1 h at the same point of the circadian rhythm at 6 months of age (n = 14-22 female mice per group). The measures of hyperactivity were average speed (M), distance moved (N), frequency in centre (O) and frequency immobile (P). LV.NAGLU, LV.NAGLU-IGFII and PRED + LV.NAGLU are all LV-mediated HSCGT-treatment groups. Error bars represent the SEM. Significant difference to wild-type is demonstrated with *P 5 0.05, **P 5 0.01, ***P 5 0.001 and ****P 5 0.0001. Other differences are indicated with a line. Lentiviral-mediated HSCGT, HSCT and prednisolone each significantly improve behaviour MPSIIIB patients exhibit increasingly severe behavioural problems as a result of accumulating neurological damage. To determine whether LV-mediated HSCGT treatment was able to ameliorate the behavioural phenotype seen in MPSIIIB mice, the open field test was conducted at 6 months of age (4 months post-transplant). Consistent with previous findings, MPSIIIB mice display a hyperactive phenotype (Langford-Smith et al., 2011b), behaving significantly different from wild-type in the four parameters tested: total distance moved, frequency of centre entries, frequency immobile and average speed ( Fig. 4M-P) . Interestingly, all treatments, including wild-type HSCT and prednisolone, where brain inflammation remains high, resulted in full correction of these behavioural phenotypes, with animals appearing indistinguishable from wild-type ( Fig. 4M-P) . Additionally improvement in these behaviours observed in prednisolone-treated mice, was further ameliorated with the addition of LV.NAGLU (Fig. 4M-O) , suggesting additional benefit with combined treatments.
Only lentiviral-mediated HSCGT is sufficient to correct astrogliosis and microgliosis in the brain
Maintenance of the neuron-microglia-astrocyte 'triad' is critical for normal brain function (Cerbai et al., 2012 ), yet enlarged lysosomes and chronic neuroinflammation with extensive microgliosis and astrocytosis is characteristic of MPSIIIB disease . Coronal brain sections were stained with lysosomal associated membrane protein 2 (LAMP2) to highlight lysosomal swelling, together with either activated astrocyte marker GFAP ( Fig. 5 and Supplementary Fig. 4 ) or neuronal marker NeuN (Fig. 6) . In wild-type, astrocytic GFAP + cells were largely absent from the cortex, striatum and thalamic regions, although staining was clearly visible in the stratum layers of the hippocampus and amygdala (Fig. 5 and Supplementary Fig. 4 ). In contrast, significant astrocytosis was apparent throughout the MPSIIIB brain, with large numbers of activated astrocytes present in the cortex, striatum and substantia nigra. No obvious changes in neuronal cell number were noted between wild-type and MPSIIIB following staining for NeuN, indicating there is little neuronal cell loss in MPSIIIB (Fig. 6) .
In wild-type brains, LAMP2 staining was punctate and more peripheral within neurons, with negligible astrocytic expression. MPSIIIB mice however exhibit significantly increased LAMP2 staining compared to wild-type, with intense large vesicular LAMP2 + lysosomes present throughout GFAP + astrocytes and in distinct locations around the nucleus of NeuN + neurons within the cortex, pyramidal regions of the hippocampus and throughout the amygdala (Figs 5 and 6 ). In the striatum and substantia nigra intense LAMP2 staining appeared restricted to GFAP + astrocytes (Fig. 5) . Thus although there is no change in neuronal cell number, the significant lysosome burden in these cells is likely to dramatically alters cellular function, leading to the neurological outcomes noted in these mice.
Prednisolone treatment resulted in minimal changes in LAMP2 staining or astrocytosis (Fig. 5) . A small reduction in the intensity of LAMP2 was present in the cortex of wild-type HSCT mice (Fig. 5A and C) , although no significant decreases in other regions of the brain compared to untreated MPSIIIB were apparent. In HSCGT mice treated with LV.NAGLU with or without prednisolone treatment or following treatment with LV.NAGLU-IGFII, significant reductions in LAMP2 staining were apparent, with little astrocytosis (GFAP + cells) noted throughout the cortex, striatum and all other regions of the brain studied ( Fig. 5 and Supplementary Fig. 4 ). LV.NAGLU consistently gave greater reductions in lysosomal swelling compared to LV.NAGLU.IGFII, but both treatments mediated reductions in lysosomal swelling in neurons and astrocytes indicating cross-correction.
Severe neuroinflammation and microgliosis in MPSIIIB is highlighted by a 47-fold increase in isolectin B4 (IB4)-positive microglia in the cortex and extensive staining throughout the MPSIIIB brain (Fig. 7A-C and Supplementary Fig.  5 ). Wild-type HSCT resulted in a small, yet significant decrease in IB4 staining; however, levels were still 33-fold over wild-type. Little effect on brain microgliosis was seen with prednisolone treatment. MPSIIIB mice treated with LV.NAGLU with or without prednisolone resulted in complete reversal of neuroinflammation, with few IB4 + cells remaining in the cortex, striatum or hippocampal brain regions (Fig. 7) . IB4 + cells did, however, remain in the amygdala, thalamic and substantia nigra regions of the brain in these mice ( Supplementary Fig. 5 ), although levels were substantially reduced compared to untreated animals. The amygdala is important in memory processing and emotional responses, thus reductions in IB4 + cells might be key for amelioration of behavioural issues. The level of correction achieved with LV.NAGLU-IGFII was not as pronounced as with LV.NAGLU, whereby IB4 + cell numbers remained elevated compared to wild-type. However, microgliosis in LV.NAGLU-IGFII animals was significantly improved compared to untreated and wild-type HSCT (Fig. 7A-C) .
MPS disease is also characterized by secondary storage of other compounds including GM2 gangliosides in the brain, which may itself propagate CNS inflammatory responses observed in GM2 mice (Jeyakumar et al., 2003) . Wildtype animals exhibit little GM2 storage in the brain (Fig.  7D-F and Supplementary Fig. 5 ). However, MPSIIIB animals have distinct punctate storage within layers V/VI of the cortex, throughout amygdala and hippocampal regions and in the zona incerta. GM2 staining was absent or low in all LV-mediated HSCGT treated mice, appearing indistinguishable from wild-type controls; however, only marginal reductions in staining were seen in wild-type HSCT mice. No apparent changes in GM2 staining were seen with prednisolone treatment alone. Therefore staining of the brain for neuroinflammatory markers suggests LVmediated HSCGT can abrogate the disease phenotype in MPSIIIB animals.
Prednisolone treatment reduces inflammation in the liver
Although no reduction in inflammation was seen in the brain of prednisolone treated mice, consistent with prednisolone being unable to cross the blood-brain barrier, cytokine analysis suggested widespread reductions in inflammatory cytokine expression in the periphery. Therefore liver from control and treated mice was stained with IB4 ( Fig. 8) . Intense IB4 staining was visible throughout the liver of untreated MPSIIIB mice compared to wildtype mice. Prednisolone treatment resulted in significant decreases in IB4 reactivity throughout the liver, with levels similar to wild-type. Wild-type HSCT and HSCGTtreated groups also exhibited significantly reduced IB4 + staining; however, combined PRED + LV.NAGLU treatment resulted in synergistic results, with levels dropping below wild-type (Fig. 8 ). This suggests prednisolone may aid reduction in disease pathology in somatic organs.
Discussion
Here we demonstrate an LV-mediated HSCGT approach to treat neuropathology in MPSIIIB (Sanfilippo disease), providing a promising treatment option for these patients. Wildtype HSCT, although providing benefit to somatic organs and increasing life span, provided insufficient NAGLU levels in the brain to improve neuropathology, as seen previously (Zheng et al., 2004; Heldermon et al., 2010) . This is similar to outcomes in Sanfilippo patients, who typically have improved lifespan without neurological correction (Vellodi et al., 1992; Prasad et al., 2008) . In contrast HSCGT with LV.NAGLU-transduced autologous haematopoietic stem cells improved all pathogenic markers, resulting in normalization of primary heparan sulphate storage, abolition of secondary substrate storage materials and significant reductions in inflammatory cytokine expression, lysosomal swelling, microgliosis and astrogliosis in the brain. Enzyme levels achieved in somatic organs were also far superior to wild-type HSCT. In this study mice were treated at $2 months of age, at which stage considerable disease burden exists Ribera et al., 2015) . Thus our LV-mediated HSCGT approach is able to successfully correct disease pathology, even when significant neuropathology already exists. Significantly in HSCGT-treated animals, restoration of brain NAGLU enzyme above $5% appeared sufficient for complete reversal of the MPSIIIB neuropathology at 6 months posttreatment. This is in contrast to a retroviral HSCGT approach previously tested in MPSIIIB (Zheng et al., 2004) , where brain correction was sporadic, with $25% wild-type brain enzyme in the highest group, but with considerable variability, with brain expression in most animals remaining low. Probable gene silencing from the LTR promoter was noted, reflecting the early generation vector design and transduction methodology used.
C-terminal fusion of IGFII to NAGLU resulted in minimal NAGLU secretion into the culture medium of CHME3 microglial cells in vitro or into blood plasma in vivo. This is in contrast to previous results in Chinese hamster ovary cells (Kan et al., 2014b ), yet considering the identical linker was used, this most likely reflects the differences in cell types used. Regardless, it is typically assumed that crosscorrection is the major mechanism for disease correction and is essential for treatment efficacy. However, restricting expression of NAGLU to the engrafted donor macrophages in the brain and thus limiting cross-correction with LV.NAGLU-IGFII, surprisingly resulted in significant reductions in neuropathology, with near identical outcomes to using the unmodified LV.NAGLU vector. Although we cannot exclude that some cross-correction remains, and that the IGFII linker may enhance uptake (Kan et al., 2014b) , despite reduced secretion, as observed by reductions in neuronal and astrocytic LAMP2, these data nevertheless suggest that correction of donor macrophages may prove as important for efficient brain correction as widespread dissemination of NAGLU to all cell types in the brain.
We were surprised that wild-type HSCT and prednisolone were able to improve hyperactivity, correcting behavioural phenotypes seen in MPSIIIB mice. However, this is consistent with previous findings in which treatment of MPSIIIB mice where prednisolone improved performance in the Morris Water Maze, significantly reduced spleen size and decreased T cell activation (DiRosario et al., 2009) . Whereas wild-type HSCT effectively delivers NAGLU enzyme to somatic organs, abolishing accumulated heparan sulphate and thereby restoring lysosomal function, the corticosteroid prednisolone acts as an anti-inflammatory. Common to both treatments is significantly reduced inflammation in the periphery, but without central brain effects. Several other studies have indicated that correction of somatic inflammation has the potential to treat disorders of neurodevelopmental origin. For example in the lysosomal storage disease infantile neuronal ceroid lipofuscinosis, intraperitoneal injections of MW151, a small-molecule anti-neuroinflammatory, was able to reduce the incidence of seizures, despite having little effect on brain pathology (Macauley et al., 2014) . Prednisolone itself is not recommended as a long-term treatment for patients due to deleterious side effects. However, our data linking a decrease in circulating inflammatory cytokines with improved behaviour indicates that treatments with a similar action to prednisolone may provide relief from at least some of the behavioural aspects of MPSIIIB disease, and has the potential to be an adjunct therapy. Although LV-mediated HSCGT alone appears sufficient to correct the CNS pathology, the benefits of prednisolone to somatic disease indicates that specifically targeted anti-inflammatories could be incorporated into therapeutic approaches for MPSIIIB.
Several other strategies to treat MPSIIIB patients are being trialled. Intracerebroventricular injection of NAGLU enzyme has proven effective in mouse models of MPSIIIB (Kan et al., 2014a) but clinical application of this approach in mucopolysaccharidosis II has been fraught with device failure issues (Muenzer et al., 2016) , with half of the enrolled patients required surgical intervention due to delivery device failure. A similar trial for MPSIIIA was unsuccessful (Jones et al., 2016) . A systemic gene therapy approach using intravenous injection of AAV9 in mice at 1 month of age was reported to achieve 42-fold over wild-type brain enzyme delivery, together with somatic NAGLU expression, glycosaminoglycan reduction and behavioural correction (Fu et al., 2011 (Fu et al., , 2017 . This approach has now been approved for a phase 1/2 clinical trial in MPSIIIB patients (IND 16671) . Nonetheless scalability remains a major challenge, requiring a significant change in manufacturing infrastructure to enable the synthesis of sufficient virus at the magnitude required to treat patients.
Targeted injection of AAV-NAGLU vectors directly into the brain of MPSIIIB mice has also been tested, leading to long-term NAGLU expression, reduced glycosaminoglycan levels and some behavioural improvements (Fu et al., 2002 (Fu et al., , 2007 (Fu et al., , 2010 Cressant et al., 2004; Heldermon et al., 2010 Heldermon et al., , 2013 . However, cellular transduction was often restricted to those cells surrounding the injection site and systemic organs remain uncorrected, something that is overcome by our HSCGT approach, as donor macrophages distribute and engraft throughout the brain and somatic organs (Wilkinson et al., 2013) . Interestingly in some studies survival was increased to 19-20 months for some animals, above what we achieve here with HSCGT. The significance of survival is, however, not clear in MPSIIIB, where the main disease pathology is in the brain. In the absence of significant neuronal cell death in the mouse model, the endpoint is typically urine retention (Gografe et al., 2009) . Scalability with the AAV approach remains problematic, with substantial increases in vector distribution and injection sites required for significant success in patients (Tardieu et al., 2017 ). An alternative is direct injection of AAV9-NAGLU into CSF, reported to result in widespread CNS targeting and some somatic correction via vector passage into circulation (Ribera et al., 2015) . The high rate of pre-existing immunity to AAV vectors in the human population, however, provides a significant obstacle for therapy, with patients often positive for neutralizing antibodies against multiple serotypes (Hareendran et al., 2013) . Generation of novel AAV serotypes is therefore essential.
In summary, here we present neurological disease correction of MPSIIIB mice by LV-mediated HSCGT, with significantly enhanced correction compared to wild-type HSCT. Critically LV-mediated HSCGT is relevant and scalable to MPSIIIB patients. Thus given the current lack of effective treatment for MPSIIIB, this study demonstrates that HSCGT alone or in combination with anti-inflammatories could be a clinically viable approach to improve the neurological function in MPSIIIB patients. Significant difference to wild-type is demonstrated with *P 5 0.05, **P 5 0.01, ***P 5 0.001 and ****P 5 0.0001. Other differences are indicated with a line.
